LUCIANA SACILOTTO FERNANDES
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
2 resultados
Resultados de Busca
Agora exibindo 1 - 2 de 2
- Coexistence of Wolff-Parkinson-White and Brugada Syndrome: Mere Curiosity?(2014) KAISER, Elisabeth; SACILOTTO, Luciana; DARRIEUX, Francisco; SOSA, EduardoThe association between Brugada syndrome (BS) and ventricular preexcitation is a rare condition, with sporadic cases already reported. We report the case of a 29-year-old man, with palpitation unrelated to physical or emotional stress. The electrocardiogram of the first visit revealed a ventricular preexcitation pattern and an end-conduction delay, with negative T wave in V-1 and intraventricular conduction disturbance in V-2 (atypical for BS). The typical aspect of BS occurred after introduction of propafenone for the prevention of atrioventricular tachycardia. We discuss the recognition of this rare association, the proarrhythmic effects of some drugs, treatment options, and prognosis.
- Late Outcome of a Randomized Study on Oral Magnesium for Premature Complexes(2014) FALCO, Cristina Nadja M. Lima De; DARRIEUX, Francisco Carlos da Costa; GRUPI, Cesar; SACILOTTO, Luciana; PISANI, Cristiano F.; LARA, Sissy; RAMIRES, Jose A. F.; SOSA, Eduardo; WU, Tan Chen; HACHUL, Denise; SCANAVACCA, MauricioBackground: Ventricular and supraventricular premature complexes (PC) are frequent and usually symptomatic. According to a previous study, magnesium pidolate (MgP) administration to symptomatic patients can improve the PC density and symptoms. Objective: To assess the late follow-up of that clinical intervention in patients treated with MgP or placebo. Methods: In the first phase of the study, 90 symptomatic and consecutive patients with PC were randomized (double-blind) to receive either MgP or placebo for 30 days. Monthly follow-up visits were conducted for 15 months to assess symptoms and control electrolytes. 24-hour Holter was performed twice, regardless of symptoms, or whenever symptoms were present. In the second phase of the study, relapsing patients, who had received MgP or placebo (crossing-over) in the first phase, were treated with MgP according to the same protocol. Results: Of the 45 patients initially treated with MgP, 17 (37.8%) relapsed during the 15-month follow-up, and the relapse time varied. Relapsing patients treated again had a statistically significant reduction in the PC density of 138.25/ hour (p < 0.001). The crossing-over patients reduced it by 247/ hour (p < 0.001). Patients who did not relapse, had a low PC frequency (3 PC/ hour). Retreated patients had a 76.5% improvement in symptom, and crossing-over patients, 71.4%. Conclusion: Some patients on MgP had relapse of symptoms and PC, indicating that MgP is neither a definitive nor a curative treatment for late follow-up. However, improvement in the PC frequency and symptoms was observed in the second phase of treatment, similar to the response in the first phase of treatment.